|
|
|
| Clinical efficacy of cervix loop electrosurgical excision procedure combined with interferon and anti-HPV biological protein dressing for treating women with cervical high-grade squamous intraepithelial lesions and high-risk human papilloma virus infection |
| 1.Affiliated Hospitial of Jiangnan University, Wuxi, 214000; 2.Nancheng Hospital of Dongguan City, Guangdong Province |
|
|
|
|
Abstract To explore the clinical efficacy of cervix loop electrosurgical excision procedure (LEEP) combined with recombinant human interferon α-2b effervescent capsules and anti-HPV bioprotein dressings for treating women with cervical high-grade squamous intraepithelial lesions (HSIL) and high-risk human papilloma virus (HPV) infection. Methods: The women with HSIL and high-risk HPV infection who underwent LEEP treatment were selected and were divided in two groups (46 cases in each group) from January 2019 to December 2020. The women in the study group were given treatment of LEEP combined with recombinant human interferon α-2b effervescent capsules and anti-HPV bioprotein dressings additionally. The clinical efficacy, the HPV viral load before and after treatment, the positive expression rates of Survivin and Ki-67, the postoperative complications rate, and the situation of high-risk HPV negative conversion during 6 and 12 months of followed up of the women were compared between the two groups. Results: The total effective rate of the treatment of cervical lesion (95.7%) of the women in the study group was significantly higher than that (82.6%) of the women in the control group. HPV viral load and positive rates of Survivin and Ki-67 were affected significantly by different time point effect, intergroup effect, time point, and intergroup interaction effect. The level of HPV viral load (6.6±0.8), and the degree decreased of the positive rates Survivin (24.0±2.9%) and Ki-67 (19.2±2.1%) of the women in the study group after treatment were significantly better than those of the women in the control group (all P＜0.05). There were no significant differences in the incidences of complications, such as cervical adhesion and other, of the women between the two groups (P＞0.05). The negative rate of the women in the study group in postoperative 6 months (87.0%) or in postoperative 12 months (93.5%) was significantly higher than that (65.2% or 78.3%) of the women in the control group (all P＜0.05). Conclusion: The clinical efficacy of LEEP combined with recombinant human interferon α-2b and anti-HPV biological protein dressing for treating the women with HSIL and high-risk HPV infection is superior to that of LEEP only, which can effectively inhibit virus proliferation and promote high-risk HPV infection returning to negative, and can reduce the postoperative recurrence rate of HSIL.
|
|
|
|
|
|
|
|
|
